Related Experiment Video
Updated: Jan 27, 2026
12:03
Evaluation of the Efficacy And Toxicity of RNAs Targeting HIV-1 Production for Use in Gene or Drug Therapy
Published on: September 5, 2016
8.2K
New targets for HIV drug discovery
Ana C Puhl1, Alfredo Garzino Demo2, Vadim A Makarov3
1Collaborations Pharmaceuticals, Inc., Main Campus Drive, Lab 3510, Raleigh, NC 27606, USA.
Drug Discovery Today
|March 20, 2019
Summary
New human immunodeficiency virus (HIV) drug targets are crucial, as nearly one million people die annually from HIV-related illnesses. Host-related and unexploited viral targets offer promising avenues for novel therapies and a potential cure.
Area of Science:
- Virology
- Drug Discovery
- Immunology
Background:
- An estimated one million global deaths annually are attributed to human immunodeficiency virus (HIV)-related illnesses.
- The ongoing need for novel therapeutic strategies against HIV persists.
- Drug resistance remains a significant challenge in managing HIV infections.
Purpose of the Study:
- To review and highlight emerging and unexploited therapeutic targets for HIV.
- To explore host-related targets that may circumvent viral drug resistance.
- To identify next-generation candidates for HIV drug discovery and cure research.
Main Methods:
- Literature review of recent advancements in HIV target identification.
- Analysis of potential host-related targets for HIV drug development.
- Evaluation of unexploited viral targets, including capsid and RNAse H.
- Assessment of targets addressing viral virulence, latency, and persistence.
Main Results:
- Several novel host-related targets have been identified, potentially offering reduced risk of drug resistance.
- Specific viral targets, such as capsid and RNAse H, remain clinically unexploited.
- Emerging targets focus on critical aspects of HIV pathogenesis, including virulence, latency, and persistence.
Conclusions:
- The reviewed targets represent promising candidates for next-generation HIV therapeutics.
- Further research into these targets could accelerate the development of new drugs and contribute to finding a cure for HIV.
- A multifaceted approach targeting both host and viral factors is essential for overcoming HIV.
Related Concept Videos
01:26Drug Discovery: Overview
11.4K
Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
11.4K
01:26Targets for Drug Action: Overview
10.2K
Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
10.2K
01:25Pharmacokinetics: Drug–Drug Interactions
428
Drug interactions occur when the pharmacological effect of one drug is altered by another substance, either enhancing or diminishing its activity. The drug whose activity is altered is known as the object drug, and the substance causing the alteration is called the agent drug or the precipitant. The net effects of these interactions are mostly undesirable, leading to decreased effectiveness or increased adverse effects. In rare cases, interactions can be beneficial, such as the enhanced...
428
01:09Bioequivalence of Drugs: Drugs with Multiple Indications
156
The concept of therapeutic equivalence (TE) in drugs with multiple indications is complex. A generic drug may be therapeutically equivalent to a brand-name product for one specific indication, but this doesn't necessarily mean it's equivalent for all other indications. Evidence of TE in one patient group and bioequivalence shown in healthy volunteers can support—but not confirm—TE for other indications. However, definitive proof requires individual clinical studies for each...
156
01:26FDA Approved Drugs: Changes to Approved Drugs
256
Post-approval, manufacturers may modify an approved new or generic drug product. Such modifications can encompass alterations in the Active Pharmaceutical Ingredient (API), manufacturing process, formulation, batch size, manufacturing site, and container closure system (FDA Guidance for Industry, April 2004). Often, a drug product may undergo multiple changes.These modifications require careful evaluation to determine their potential impact on the drug product's identity, strength, quality,...
256
01:27Factors Influencing Drug Absorption: Drug Dissolution
1.2K
The pharmacokinetic journey of drugs from solid oral dosage forms into systemic circulation is multifaceted. It begins with disintegration, a prerequisite ensuring a solid dosage form's subdivision into minute particles. Dissolution occurs next as these granulated entities solubilize in gastrointestinal fluids. This solubilization is crucial for the succeeding stage, permeation, which describes the traversal of the drug across the intestinal membrane and its subsequent entry into the blood...
1.2K